PET/MRI for evaluation of patients with pancreatic cancer

被引：3

作者：

Duncan, Zoey N. ^{[1
]}

Summerlin, David ^{[2
]}

West, Janelle T. ^{[2
]}

Packard, Annie T. ^{[3
]}

Morgan, Desiree E. ^{[2
]}

Galgano, Samuel J. ^{[2
]}

机构：

[1] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA

[2] Univ Alabama Birmingham, Dept Radiol, Med Ctr, Birmingham, AL 35294 USA

[3] Mayo Clin, Dept Radiol, Rochester, MN USA

来源：

ABDOMINAL RADIOLOGY | 2023年 / 48卷 / 12期

关键词：

Pancreatic cancer; PET; MRI; Neuroendocrine tumor; EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY; ROW COMPUTED-TOMOGRAPHY; DUCTAL ADENOCARCINOMA; IMAGING DIAGNOSIS; CT; PET/CT; MANAGEMENT; GUIDELINE; SOCIETY;

D O I：

10.1007/s00261-023-03943-9

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Pancreatic cancers are the third leading cause of cancer-related death in the USA and outcomes remain poor despite improvements in imaging and treatment paradigms. Currently, computed tomography (CT) and magnetic resonance imaging (MRI) are frequently utilized for staging and restaging of these malignancies, but positron emission tomography (PET)/CT can play a role in troubleshooting and improve whole-body staging. PET/MRI is a novel imaging modality that allows for simultaneous acquisition of PET and MRI images, leading to improved image quality and potential increased sensitivity. Early studies suggest that PET/MRI may play a larger role in pancreatic cancer imaging in future. This manuscript will briefly discuss current imaging approaches to pancreatic cancer and outline existing evidence and published data supporting the use of PET/MRI for pancreatic cancers.

引用

页码：3601 / 3609

页数：9